Jin‐Ji Yang

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 992 citations

Medicine, Immunology, Oncology +17

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y.S. Li, Bo Jiang, Jin‐Ji Yang et al. · Annals of Oncology · 2018 · 330 citations · Full text

Medicine, Genetics, Oncology +17

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang et al. · Journal of Thoracic Oncology · 2016 · 322 citations · Full text

Medicine, Molecular Medicine, Oncology +14

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang et al. · Molecular Cancer · 2010 · 298 citations · Full text

Medicine, Oncology, Pathology +17

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Qun Wang, Weimin Mao, Lin Wu et al. · Journal of Clinical Oncology · 2020 · 279 citations · Full text

Medicine, Oncology, Pharmacology +15